ÂÜÀòÂÒÂ×

Amy Rabourn serves as SVP of Finance of Ocuphire. She has 18 years of finance and accounting experience, including public company, with a focus on life sciences. In her most recent role, she was Director of Finance at Gemphire Therapeutics, Inc. which merged with NeuroBo Pharmaceuticals, Inc. in December of 2019. She was with the company since inception as its first finance employee. She implemented processes and procedures and supported the Company through private fund raising and its IPO in August of 2016. She oversaw daily financial transactions, performed budgeting and forecasting, and managed the financial reviews and audit, SEC filings and tax preparation. Upon departure of the CFO in September of 2018, she assumed additional responsibilities including management of insurance and HR activities and reporting to the Audit Committee. After the merger, she continued as a consultant to NeuroBo in the same role as they transitioned to public company status. Prior to that, she held a position as Controller of a software start-up, performed financial consulting in the life sciences space and worked in Finance at Pfizer. She is a licensed CPA with public accounting experience from PricewaterhouseCoopers, LLP where she worked in the audit practice. Amy is a graduate of the University of Michigan where she earned a MAcc (Master of Accounting) and BBA with a Finance and Accounting concentration.